Spyre Therapeutics Inc. (SYRE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $90.15 (-2.73%), Market cap $6.25B, 52-week low–high $14.68 ~ $76.43.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4
Financial statements, price targets, institutional (13F) holdings and related news for Spyre Therapeutics Inc. are updated in real time on BlackAll Trade.
Spyre Therapeutics Inc. trades at $90.15 (-2.73%). Real-time quotes and charts are available on BlackAll Trade.
Spyre Therapeutics Inc. has a market cap of about $6.25B.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company devel